| renal-cell carcinoma (advanced) | versus No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| METEOR, 2015 | cabozantinib vs everolimus | OS 0.67 [0.51; 0.89] PFS 0.58 [0.45; 0.75] | | | | CABOSUN, 2017 | cabozantinib vs sunitinib | PFS 0.66 [0.46; 0.95] median 8.2 mo vs. 5.6 mo | | |
| Trial | Treatments | Patients | Method |
|---|
| METEOR, 2015 | cabozantinib at a dose of 60 mg
daily (n=330) vs. everolimus at a dose of 10 mg daily (n=328) | patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy | open-label Parallel groups Sample size: 330/328 Primary endpoint: PFS FU duration: phase 3 | | CABOSUN, 2017 | cabozantinib (60 mg once per day) (n=79) vs. sunitinib (50 mg once per day; 4 weeks on, 2 weeks off). (n=78) | untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria | open-label Parallel groups Sample size: 79/78 Primary endpoint: PFS FU duration: phase 2 |
|
